Replies to post #233290 on Biotech Values

[ronpopeil]

Yes plus the dropped their Hem A program which was at the end of their PR too! Not sure that’s a huge deal but still noted

[DewDiligence]

QURE -24%/PM on FDA clinical hold in hemophilia-B trial:

http://www.globenewswire.com/news-release/2020/12/21/2148517/0/en/uniQure-Announces-Clinical-Update-on-Hemophilia-B-Gene-Therapy-Program.html

The clinical hold was initiated following the submission of a safety report in mid-December relating to a possibly related serious adverse event associated with a preliminary diagnosis of hepatocellular carcinoma (HCC), a form of liver cancer, in one patient in the HOPE-B trial that was treated with etranacogene dezaparvovec (AMT-061) in October 2019.